Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers: New-onset diabetes mellitus stratified by statin use.
Juyoung ShinHyunah KimHyeon Woo YimJu Han KimSuehyun LeeHun Sung KimPublished in: Journal of clinical pharmacy and therapeutics (2021)
Patients taking ACEIs are less likely to develop NODM than patients taking ARBs, irrespective of statin use. Patients' conditions, including the risk of NODM, should be considered before prescribing ACEIs or ARBs. Future randomized clinical trials are needed to clarify further the relationship between ACEIs and ARBs and their effect on NODM.
Keyphrases
- end stage renal disease
- angiotensin converting enzyme
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- angiotensin ii
- cardiovascular disease
- prognostic factors
- primary care
- emergency department
- coronary artery disease
- patient reported outcomes
- adipose tissue
- skeletal muscle
- patient reported